The winning entrant will demonstrate that their concept offers a novel approach with the potential to transform outcomes for patients or meet a previously unmet clinical need.

Judges will seek evidence of results demonstrating its potential to improve care, operator experience or efficiency and will be mindful of the opportunity for commercialisation of the concept.

To be eligible, a product or solution entry must have been produced for public trial or general availability after Thursday, 1 July 2021 (two-year window). Judges will be looking for:

• Technological advancement: Recognising innovations that have significantly advanced the field of interventional cardiology through the development of new devices, equipment, or technologies.
• Clinical impact: Acknowledging innovations that have demonstrated clinical benefits in the diagnosis, treatment, or management of cardiovascular disease, resulting in improved patient outcomes.
• Safety and efficacy: Recognising innovations that have demonstrated exceptional safety profiles and proven effectiveness in the treatment of cardiovascular conditions, ensuring better patient outcomes while minimising risks.
  

The winning entrant will demonstrate that their concept offers a novel approach with the potential to transform outcomes for patients or meet a previously unmet clinical need.

Judges will seek evidence of results demonstrating its potential to improve care, operator experience or efficiency and will be mindful of the reproducibility of the concept.

To be eligible, a product or solution entry must have been produced for public trial or general availability after Thursday, 1 July 2021 (two-year window).

• Novel techniques: Recognising innovations that have advanced the range of treatment options available to cardiac surgeons and improved patient care.
• Clinical impact: Acknowledging innovations that have demonstrated clinical benefits in the diagnosis, treatment, or management of cardiovascular disease, resulting in improved patient outcomes.
• Safety and efficacy: Recognising innovations that have demonstrated exceptional safety profiles and proven effectiveness in the treatment of cardiovascular conditions, ensuring better patient outcomes while minimising risks.
  

The entrant will be able to demonstrate the effectiveness of their solution through robust scientific data and judges will be mindful of the ease of implementation of the concept.

To be eligible, a product or solution entry must have been produced for public trial or general availability after Thursday, 1 July 2021 (two-year window).

Judges will be looking for:

• Impact on safety: The award recognises innovations that have a measurable and positive impact on patient or operator safety in cardiovascular healthcare. The innovation should address specific safety concerns or challenges related to procedures, devices, equipment, or workflows, ultimately reducing risks and improving overall safety outcomes. 
• Clinical relevance: Judges will consider innovations that directly address safety issues encountered in real-world clinical practice. The innovation should be applicable to a broad range of cardiovascular healthcare settings and have the potential to impact a significant number of patients and healthcare providers.
• Practical implementation: Entrants will bring forward innovations that are practical and feasible to implement in clinical settings. Consideration will be given to factors such as ease of integration into existing workflows, compatibility with standard practices, cost-effectiveness, and scalability across different healthcare environments.
  

To be eligible, a product or solution entry must have been produced for public trial or general availability after Thursday, 1 July 2021 (two-year window).

Judges will be looking for: 

• Clinical impact: Judges will recognise innovations that have a direct and positive impact on clinical practice and patient care. The technology or technique should demonstrate potential for improving diagnostic accuracy, patient outcomes, or treatment planning.
• Scientific rigour: Entrants should demonstrate that their solution is backed by rigorous scientific research and evidence. The development and implementation of the innovation should be supported by well-designed studies, clinical trials, or experimental validation, demonstrating its effectiveness and reliability.
• Practical applicability: Factors such as cost-effectiveness, ease of integration into existing imaging workflows, and compatibility with standard imaging protocols should be taken into account.
  

To be eligible, the product launch must have commenced after Thursday, 1 July 2021 (two-year window).

Judges will be looking for:

• Clinical adoption and impact: Judges will seek to understand the product's adoption and impact in clinical practice. Consideration should be given to its integration into routine care, usage by healthcare providers, improvements in patient outcomes, and positive clinical feedback or evidence of efficacy.
• Marketing and branding strategy: The award will recognise the effectiveness of the marketing and branding strategy employed during the product launch. Consideration will be given to the clarity and consistency of messaging, the targeting of the intended audience, the use of appropriate marketing channels, and the overall impact of the marketing campaign on product awareness and adoption.
  

Judges will be looking for:

• Technological advancement: Priority will be given digital innovations that leverage emerging technologies and demonstrate significant advancements in the field of cardiovascular healthcare. This could include but is not limited to artificial intelligence (AI), machine learning, data analytics, telemedicine, wearables, mobile applications, virtual reality, or remote monitoring solutions.
• Clinical impact and patient outcomes: Points will be awarded for solutions that have a direct and positive impact on patient outcomes and the delivery of care. The digital solution should improve diagnosis, treatment, monitoring, or patient engagement, ultimately leading to better clinical outcomes, enhanced patient experience, or improved efficiency of care.
• User experience and interface design: Judges will assess the user experience and interface design of the digital solution. It should be intuitive, user-friendly, and designed with a focus on healthcare provider and patient needs, ensuring ease of use, seamless integration into existing workflows, and accessibility for all users. 
• Scalability and integration: Recognition will be given for solutions that can be easily scaled and integrated into existing healthcare systems and infrastructures. The solution should demonstrate compatibility with different healthcare settings, interoperability with other systems, and the potential for widespread adoption and implementation.
  

Judges will be looking for:

• Inclusive and equitable care: The award values efforts to promote inclusive and equitable care for diverse populations affected by cardiovascular disease. The submission should focus on addressing disparities, reducing healthcare inequalities, and ensuring access to high-quality care for individuals from diverse backgrounds, including racial, ethnic, socioeconomic, and cultural minorities.
• Culturally competent care: The judges will assess contributions that prioritise cultural competence in cardiovascular care. This includes initiatives that promote understanding, respect, and sensitivity toward cultural differences and address cultural beliefs, practices, and values that may influence patient care and treatment outcomes.
  

Judges will be looking for: 

• Clinical excellence: Judges will consider the individual's demonstrated clinical excellence and expertise in cardiovascular care. This includes a track record of providing exceptional patient care, diagnostic accuracy, treatment efficacy, and outcomes, as well as recognition from peers and patients for their clinical skills. 
• Research and publications: Value will be placed against the individual's research contributions and publications. This includes a substantial body of high-quality research, peer-reviewed publications, and influential scientific contributions that have contributed to the knowledge and understanding of cardiovascular diseases and their treatment.
• Leadership and mentorship: Consideration will also be given to the individual's leadership and mentorship in the field of cardiovascular care. This includes leadership roles in professional organisations, teaching and mentorship of students, residents, or fellows, and active involvement in advancing the education and professional development of future generations of cardiovascular healthcare providers.
  

Judges will be looking for:

• Academic and professional accomplishments: Judges will consider the individual's academic and professional accomplishments in the field of cardiovascular care. This includes educational achievements, or fellowships, as well as early contributions to research, publications, or presentations at conferences.
• Clinical competence: The entrant will demonstrate clinical competence and expertise in cardiovascular care. This includes their ability to provide high-quality patient care, demonstrate diagnostic and treatment skills, and show promise in achieving positive patient outcomes. 
• Innovation and research potential: Successful submissions will provide evidence of innovative thinking and research potential in the field of cardiovascular care. This includes involvement in research projects, participation in studies, and the development of novel ideas, approaches, or technologies that have the potential to advance the field.
  

Judges will be looking for: 

• Interdisciplinary collaboration: Judges will look for evidence of the heart team's ability to effectively collaborate and work together across disciplines. This includes professionals from various specialties involved in cardiovascular care, such as cardiologists, cardiac surgeons, nurses, anaesthesiologists, imaging specialists, and other relevant specialisms.
• Patient outcomes and quality of care: Entrants should demonstrate the heart team's impact on patient outcomes and the delivery of high-quality care. This includes evaluating measures such as mortality rates, complication rates, length of hospital stay, patient satisfaction, and adherence to evidence-based guidelines and best practices. 
• Complex case management: Judges will consider the heart team's expertise in managing complex cases and providing comprehensive, multidisciplinary care. This includes successfully handling challenging cardiovascular conditions, intricate procedures, or cases involving multiple comorbidities, and achieving favourable outcomes.
  

Judges will be looking for evidence of:

• Strategic vision and execution: Entrants should demonstrate the individual’s strategic vision for the company and their ability to effectively execute and achieve goals. This includes their ability to navigate the dynamic landscape of the medtech industry, identify opportu-nities, and develop a clear roadmap for growth and success.
• Industry leadership and influence: Successful entrants will demonstrate leadership and influence within the medtech industry. This includes thought leadership and contributions to shaping industry policies, standards, and best practices. 
• Product innovation and market impact: Judges will look for evidence of the CEO's leadership in driving product innovation and market impact. This includes introducing groundbreaking technologies, devices, or solutions that address unmet needs in cardiovascular care, positively impacting patient outcomes, and driving market competitiveness.
  

Judges will be looking for:

• Creativity and innovation: Judges will look for submissions that value the campaign's creativity and innovation in engaging the target audience. This includes the use of innovative communication channels, compelling visuals, interactive elements, storytelling, or other creative strategies that capture attention and motivate behavior change.
• Effectiveness and impact: Each submission will be evaluated according to the campaign's effectiveness in achieving its objectives and the impact on the target audience. This includes assessing measurable outcomes, such as changes in behaviour, knowledge, attitudes, or uptake of preventive measures, and the potential for sustained impact in reducing cardiovascular risk.
• Reach and engagement: Judges will consider the campaign's reach and level of audience engagement. This includes evaluating the number of individuals reached, the frequency and duration of exposure to campaign messages, and the level of engagement, such as interactions, social media shares, or participation in campaign activities.
  

Judges will be looking for: 

• Clear educational objectives: Judges will assess the campaign's clear objec-tives and goals. This includes a well-defined focus on providing valuable and accurate information, raising awareness, improving knowledge and understand-ing, or promoting best practices in car-diovascular healthcare. 
• Educational strategies and methods: Entrants should provide examples of the campaign's educational strategies and methods. This includes the use of effec-tive instructional techniques, such as clear and concise messaging, visual aids, interactive elements, case studies, or multimedia resources, to engage and fa-cilitate learning among the target audi-ence.
• Engagement and interaction: The award should consider the campaign's ability to engage and interact with the target audience. This includes providing opportunities for active participation, encouraging questions and dialogue, fa-cilitating discussions or workshops, or incorporating feedback mechanisms to enhance the learning experience.
  

Eligible entrants could include collaborations in research, healthcare provision or education.

Judges will be looking for: 

• Interdisciplinary collaboration: Judges will seek evidence of the collaboration's ability to bring together professionals from different disciplines and specialties within the cardiovascular care field.
• Partnerships and engagement: The entrant should demonstrate the collaboration's ability to establish strong partnerships and engage relevant stakeholders. This includes collaborations between healthcare providers, industry partners, academic institutions, patient advocacy groups, and other entities that have contributed to the success of the collaboration and its impact on cardiovascular care. 
• Sustainability and longevity: Consideration will be given to the collaboration's sustainability and long-term viability. This includes evaluating the collaboration's ability to adapt to changing healthcare landscapes, secure funding or resources, maintain momentum, and continue making a positive impact on cardiovascular care over an extended period.
  

Judges will be looking for: 

• Environmental impact: Entrants should detail the extent of the campaign, initiative, or innovation's positive impact on environmental sustainability within cardiovascular care. This includes evaluating its ability to reduce carbon footprint, minimise waste generation, conserve resources, or mitigate environmental harm associated with healthcare practices. 
• Measurable outcomes: Judges will assess the measurable outcomes and improvements in environmental sustainability. This includes evaluating specific metrics, such as reduction in greenhouse gas emissions, waste generation, or resource consumption, and assessing the overall ecological footprint of the cardiovascular care delivery.
• Long-term commitment: Consideration will be given to the commitment and dedication of the campaign, initiative, or innovation to long-term environmental sustainability within cardiovascular care. This includes evidence of ongoing efforts, continuous improvement, and a strategic roadmap for further advancing sustainability goals in the future.
  

Judges will be looking for:

• Scientific impact: The research should demonstrate a high level of scientific excellence and innovation. It should present novel findings, contribute to advancing knowledge in cardiovascular care, and have the potential to shape the future of the field.
• Clinical relevance: The research should have direct relevance to clinical practice and patient care. It should address important clinical questions, improve understanding of cardiovascular diseases or their management, and have the potential to lead to better patient outcomes or innovative treatment approaches.
• Methodological rigour: The research should demonstrate robust and rigorous scientific methods. Judges will evaluate the quality of study design, sample size, data collection, analysis, and interpretation.
• Translational potential: The research should have the potential for practical application and translation into clinical practice.
• Impact on Practice: Judges will look for research that has made a significant impact on clinical practice or influenced guidelines, protocols, or standards of care in cardiovascular healthcare.